{
    "id": "35cd2705-eb39-aaaa-e063-6294a90a66c9",
    "indications": "FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.",
    "contraindications": "Recommended Dose: 1.34 mg once daily with or without food for 21 days on treatment followed by 7 days off treatment (28-day cycle) until disease progression or unacceptable toxicity. ( 2.1 ) Dose interruptions and/or dose reduction may be needed to manage adverse reactions. ( 2.2 ) For patients with moderate hepatic impairment, reduce the dose to 0.89 mg for 21 days on treatment followed by 7 days off treatment (28-day cycle). ( 2.3 )",
    "adverseReactions": "None.",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TIVOZANIB HYDROCHLORIDE",
            "code": "8A9H4VK35Z"
        }
    ],
    "organization": "AVEO Pharmaceuticals, Inc.",
    "name": "FOTIVDA",
    "effectiveTime": "20250523"
}